Trial
NCT01114503
A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Graves Ophthalmopathy
Intervention
Otelixizumab - low dose
Why stopped
Clinical study in Graves' ophthalmopathy terminated until there is a better understanding of an efficacious dose with Otelixizumab from other clinical studies.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-10-30